tau-protein Targeted Therapeutics is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Tau-targeted therapeutics encompass a broad class of investigational treatments designed to reduce, neutralize, or prevent the pathological accumulation of tau protein] in alzheimers and other tauopathies including ftd, psp, and corticobasal-degeneration. While anti-amyloid-therapeutics such as lecanemab and donanemab target the amyloid, tau-directed approaches aim to address the pathological cascade most closely correlated with neuronal death and cognitive decline [1][2].
Tau pathology] — including hyperphosphorylation, aggregation into neurofibrillary tangles, and prion-like-spreading through connected brain regions — correlates more strongly with neurodegeneration and cognitive decline than amyloid burden [3]. This has motivated intensive development of anti-tau strategies across multiple modalities: passive immunotherapy, antisense oligonucleotides, small-molecule aggregation inhibitors, and kinase inhibitors.
As of 2025, twelve anti-tau antibodies have entered clinical trials, with seven still in active clinical testing. No tau-targeted therapy has yet achieved regulatory approval, but promising biomarker data — particularly reduction of tau PET signal and CSF tau biomarkers — are encouraging continued development [2:1].
Anti-tau monoclonal antibodies represent the most advanced modality in tau-targeted drug development. These antibodies target different epitopes and forms of tau protein, aiming to neutralize extracellular tau species, block cell-to-cell tau propagation], or enhance clearance of intracellular tau aggregates.
The first generation of anti-tau antibodies targeted the N-terminal region of tau, based on the rationale that N-terminal fragments are abundant in CSF and may mediate intercellular tau transfer. However, these antibodies have been universally unsuccessful [4]:
Gosuranemab (BIIB092, Bristol-Myers Squibb): Targeted the N-terminal fragment of tau. Despite reducing CSF free N-terminal tau by up to 98%, gosuranemab failed to slow cognitive decline in Phase 2 trials in both AD and PSP. The disconnect between biomarker engagement and clinical efficacy suggested that N-terminal tau fragments may not be the pathologically relevant species.
Tilavonemab (ABBV-8E12, AbbVie): Also targeted N-terminal tau. Failed in Phase 2 trials for both PSP and AD, with no significant effect on clinical decline or tau PET signal.
Zagotenemab (LY3303560, Eli Lilly): A humanized version of the MC1 antibody targeting a conformational N-terminal epitope. Discontinued after failing Phase 2 in AD.
A systematic review and network meta-analysis comparing these four antibodies concluded that none demonstrated significant clinical benefit over placebo in AD patients [4:1].
Second-generation anti-tau antibodies target the microtubule-binding region (MTBR) or mid-domain of tau, which is more directly involved in aggregation and prion-like seeding. These approaches show more promising preclinical and early clinical data [2:2]:
E2814 (Etalanetug, Eisai): A human IgG1 antibody that binds to MTBR-tau, specifically targeting the region involved in tau aggregation and cell-to-cell spreading. In the Phase 1b Study 103 conducted in dominantly inherited AD (DIAD) patients, E2814 demonstrated [5]:
E2814 is currently being evaluated in two Phase 2/3 studies [5:1]:
DIAN-TU Tau NexGen Platform Study (NCT05269394): Fully enrolled with 197 participants (originally planned 168). Running through 2028. Primary endpoints: tau PET measurement in symptomatic cohort, CSF p-tau217/total tau ratio in asymptomatic population.
Phase 2 Dose-Finding Study with Lecanemab (NCT06602258): Enrolling 105 participants with MCI due to AD. Testing four dose levels of E2814 plus weekly lecanemab for 18 months. Primary endpoint: change in CSF MTBR-tau-243 at 6 months. Expected completion August 2027.
JNJ-63733657 (Posdinemab, Johnson & Johnson): Targets the phosphorylated mid-domain region of tau (p-tau217 epitope). Phase 2 trial (NCT04619420) completed with 523 participants in January 2026 [6]. In November 2025, the company stopped the trial after a scheduled data review found no slowing of cognitive decline compared to placebo, and ended development of posdinemab. In Phase 1, posdinemab significantly reduced CSF p-tau217 levels, demonstrating target engagement.
Bepranemab (UCB0107, UCB): Targets the mid-domain of tau (residues 235-246), involved in cell-to-cell propagation. Phase 2a TOGETHER trial with 466 participants completed in May 2024 [7]:
Semorinemab (Genentech/AC Immune): An IgG4 antibody targeting extracellular tau with reduced effector function. The Phase 2 LAURIET trial in mild-to-moderate AD showed slowing on one cognitive test (ADAS-Cog) but no improvement on other cognitive or functional outcomes [8]. Genentech ended its collaboration with AC Immune in January 2024.
BMS-986446 (Bristol-Myers Squibb): Currently in Phase 2 (NCT06268886) enrolling 475 participants with early AD [9]:
MK-2214 (Merck): Phase 1 trials ongoing in healthy subjects and AD/MCI patients, with Phase 2 data expected by end of 2025.
Lu AF87908 (Lundbeck): Completed Phase 1 safety study in July 2023; further development status unclear.
APNmAb005 (APRINOIA Therapeutics): Targeting aggregated tau; in early clinical development.
PNT001 (Pinteon Therapeutics): Targets cis-p-tau, a specific pathological conformation of phosphorylated tau found after traumatic brain injury. In Phase 1/2 for traumatic-brain-injury and AD.
PRX005 (Prothena): Targets MTBR-tau; in early clinical development.
Antisense oligonucleotides offer a fundamentally different approach: rather than targeting existing tau protein, ASOs reduce tau production at the mRNA level by promoting degradation of MAPT gene transcripts via RNase H-mediated cleavage [10].
BIIB080 (IONIS-MAPTRx, Biogen/Ionis): The most advanced tau ASO, currently in Phase 2. This antisense-oligonucleotide-therapy targets mapt mRNA in the central nervous system and is administered intrathecally [10:1][11]:
The advantage of ASOs over immunotherapy is their ability to reduce both intracellular and extracellular tau by blocking production at the source. However, intrathecal administration (lumbar puncture) is more burdensome than IV or SC antibody infusions.
NIO752 (Novartis): Another anti-mapt ASO in early clinical development with an alternative chemical modification for enhanced potency and durability.
Small molecules that directly inhibit tau aggregation offer the potential for oral administration but have faced significant challenges [1:1]:
LMTX (Hydromethylthionine mesylate, TauRx): A methylthioninium derivative that inhibits tau aggregation. In Phase 3 trials, LMTX failed as an add-on therapy to existing AD treatments. However, post-hoc analyses suggested possible benefit as monotherapy. A subsequent trial (LUCIDITY) in mild cognitive impairment is evaluating LMTX as monotherapy, with mixed preliminary results. The clinical development of LMTX remains controversial.
Tau hyperphosphorylation] is driven by several kinases, including gsk3-beta, cdk5, and Fyn kinase. Targeting these kinases could reduce pathological tau phosphorylation:
The challenge with kinase inhibitors is selectivity — gsk3-beta and cdk5 have hundreds of substrates beyond tau, and broad kinase inhibition causes dose-limiting toxicity.
Beyond phosphorylation, tau undergoes acetylation, ubiquitination, SUMOylation, and O-GlcNAcylation. Modulating these modifications represents an emerging strategy:
Active immunization approaches aim to induce the patient's own immune system to produce anti-tau antibodies:
A growing consensus in the field holds that targeting tau alone — or amyloid alone — may be insufficient for meaningful disease modification. Combination strategies are being actively pursued [1:2]:
The most promising combination approach pairs amyloid-clearing antibodies with tau-targeting agents. The rationale is that amyloid pathology drives tau spreading, so removing amyloid upstream while simultaneously blocking tau propagation could produce synergistic benefit:
Combining tau-targeting with neuroinflammation modulation could address the inflammatory amplification of tau pathology. microglia can measure treatment effects on tau burden in vivo.
The study of Tau Targeted Therapeutics has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Additional evidence sources: [13] [14] [15] [16] [17] [18] [11:1]
| Class | Example Drugs | Mechanism | Stage |
|---|---|---|---|
| Aggregation Inhibitors | LMTX, methylene blue | Aβ/Tau aggregation | Phase 3 |
| Kinase Inhibitors | Tideglusib, lithium | GSK-3β inhibition | Phase 2 |
| Microtubule Stabilizers | Davunetide, paclitaxel | Tau-MT binding | Preclinical |
| Immunotherapy | AADvac1, ABBV-8E12 | Antibody clearance | Phase 2 |
Congdon EE, Ji C, Bhatt DK, et al. Tau-targeting therapies for Alzheimer's Disease: current status and future directions. Nature Reviews Neurology. 2023. ↩︎ ↩︎ ↩︎
Guo Y, Li S, Bhatt DK, et al. Tau immunotherapies for alzheimers and related tauopathies: status of trials and insights from preclinical studies. Molecular Neurodegeneration. 2024. ↩︎ ↩︎ ↩︎
Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer's Disease: synapse loss is the major correlate of cognitive impairment. Annals of Neurology. 1991. ↩︎
Zhang X, et al. Comparative efficacy and safety of Gosuranemab, Semorinemab, Tilavonemab, and Zagotenemab in patients with Alzheimer's Disease: a systematic review and network meta-analysis. Frontiers in Aging Neuroscience. 2024. ↩︎ ↩︎
ALZFORUM. Posdinemab. ↩︎
ALZFORUM. Bepranemab. ↩︎
Teng E, Manser PT, Bhatt DK, et al. Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer's Disease: Lauriet. Neurology. 2022. ↩︎
ALZFORUM. BMS-986446. ↩︎
Mummery CJ, Borjesson-Hanson A, Bhatt DK, et al. Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer's Disease: a phase 1b, randomized, placebo-controlled trial. Nature Medicine. 2023. ↩︎ ↩︎
BIIB080 Study Group. Exploratory analyses of clinical outcomes from the BIIB080 phase 1b study in mild Alzheimer's disease. Nature Aging. 2026. ↩︎
Biogen. BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's Disease. 2025. ↩︎
Biogen and Ionis. Positive topline clinical data on investigational Alzheimer's Disease treatment at AAIC. ↩︎
Jadhav S, et al. Current Status of Clinical Trials on Tau Immunotherapies. Drugs. 2019. ↩︎
Sopko R, et al. Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies. Journal of Prevention of Alzheimer's Disease. 2024. ↩︎
ALZFORUM. Semorinemab. ↩︎
ALZFORUM. Bepranemab. ↩︎